Panax notoginseng flower protects against diabetic cardiomyopathy by regulating the ACSL4/ALOX15 pathway
Frontiers in Pharmacology · 27.03.2026 · 17
DOI: 10.3389/fphar.2026.1780442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 27.03.2026. Verfasst von Yue Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of TCM Chemistry, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amway Corporation.
Abstract (Originalsprache)
Background
Panax notoginseng (Burk.) F. H. Chen flower (SQH), a common traditional Chinese medicine and edible food, has long been shown to protect against diabetes. However, the protective effects of SQH against diabetic cardiomyopathy (DbCM) and its potential mechanisms are not yet understood. Aim of the Study This study aimed to analyze the therapeutic effects of the flowers of Panax notoginseng (SQH) on DbCM and elucidate its molecular mechanisms. Materials and Methods The in vitro model of DbCM was established using palmitate-treated H9c2 cardiomyocyte. A high-fat diet (HFD) in conjunction with streptozotocin (STZ)-induced DbCM mouse model was utilized to validate the cardioprotective effects and mechanism of SQH. Transcriptomic analysis was used to examine the potential mechanisms, followed by both in vitro and in vivo validation of key protein expression levels in the ACSL4/ALOX15 signaling pathway.
Results
In vitro , SQH treatment significantly protected H9c2 cells from palmitic acid (PA)-induced injury by reducing lipid peroxidation and improving mitochondrial membrane function. Transcriptomic data indicated that SQH influenced ferroptosis-related pathways. Moreover, SQH suppressed the ACSL4/ALOX15 pathway, leading to decreased levels of the key lipid peroxidation product 12-HETE and upregulation of GPX4. In DbCM mice, SQH administration improved glucose homeostasis, attenuated cardiac dysfunction, and reduced myocardial lipid peroxidation.
Conclusion
This study demonstrated that SQH ameliorated DbCM injury primarily by inhibiting ACSL4/ALOX15-mediated ferroptosis. These findings not only highlight Panax notoginseng flower as a promising therapeutic candidate for the early intervention of DbCM but also reveal the underlying mechanism of SQH’s protective effect.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of TCM Chemistry, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Healthy Aging Research Center, Amway (Shanghai) Innovation and Science Co., Ltd., Shanghai, China.
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
- Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
- Cardiovascular Research Institute, University of Alberta, Edmonton, AB, Canada.
Förderung
- Amway Corporation
Zitieren
APA
Zhou, Y., Ouyang, L., Dong, L., Zhang, X., Du, J., Sun, S., Ussher, J. R., Chan, J. S. F., Chen, L., Huang, D., & Li, Y. (2026). Panax notoginseng flower protects against diabetic cardiomyopathy by regulating the ACSL4/ALOX15 pathway. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1780442
Vancouver
Zhou Y, Ouyang L, Dong L, Zhang X, Du J, Sun S, et al. Panax notoginseng flower protects against diabetic cardiomyopathy by regulating the ACSL4/ALOX15 pathway. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1780442
BibTeX
@article{Zhou2026,
author = {Zhou, Yue and Ouyang, Limin and Dong, Linyue and Zhang, Xue and Du, Jun and Sun, Shuai and Ussher, John R and Chan, Jordan S F and Chen, Liang and Huang, Doudou and Li, Yiming},
title = {Panax notoginseng flower protects against diabetic cardiomyopathy by regulating the ACSL4/ALOX15 pathway},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1780442}
}
EUVIMED